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Summary 
Serologic testing for hepatitis B surface antigen (HBsAg) is the primary way to identify persons with chronic hepatitis B virus 
(HBV) infection. Testing has been recommended previously for pregnant women, infants born to HBsAg-positive mothers, house­
hold contacts and sex partners of HBV-infected persons, persons born in countries with HBsAg prevalence of >8%, persons who 
are the source of blood or body fluid exposures that might warrant postexposure prophylaxis (e.g., needlestick injury to a health-
care worker or sexual assault), and persons infected with human immunodeficiency virus. This report updates and expands 
previous CDC guidelines for HBsAg testing and includes new recommendations for public health evaluation and management 
for chronically infected persons and their contacts. Routine testing for HBsAg now is recommended for additional populations 
with HBsAg prevalence of >2%: persons born in geographic regions with HBsAg prevalence of >2%, men who have sex with men, 
and injection-drug users. Implementation of these recommendations will require expertise and resources to integrate HBsAg 
screening in prevention and care settings serving populations recommended for HBsAg testing. This report is intended to serve as 
a resource for public health officials, organizations, and health-care professionals involved in the development, delivery, and 
evaluation of prevention and clinical services. 
Introduction	 United States. Persons with chronic HBV infection can 
remain asymptomatic for years, unaware of their infections 
Chronic infection with hepatitis B virus (HBV) is a com­
and of their risks for transmitting the virus to others and for 
mon cause of death associated with liver failure, cirrhosis, and 
having serious liver disease later in life. Early identification of
liver cancer. Worldwide, approximately 350 million persons 
persons with chronic HBV infection permits the identifica­
have chronic HBV infection, and an estimated 620,000 per­
tion and vaccination of susceptible household contacts and
sons die annually from HBV-related liver disease (1,2). Hepa­
sex partners, thereby interrupting ongoing transmission. 
titis B vaccination is highly effective in preventing infection 
All persons with chronic HBV infection need medical man-
with HBV and consequent acute and chronic liver disease. In 
agement to monitor the onset and progression of liver disease 
the United States, the number of newly acquired HBV infec­
and liver cancer. Safe and effective antiviral agents now are 
tions has declined substantially as the result of the implemen­
available to treat chronic hepatitis B, providing a greater 
tation of a comprehensive national immunization program 
imperative to identify persons who might benefit from medi­
(3–5). However, the prevalence of chronic HBV infection 
cal evaluation, management, and antiviral therapy and other
remains high; in 2006, approximately 800,000–1.4 million 
treatment when indicated. The majority of the medications 
U.S. residents were living with chronic HBV infection 
now in use for hepatitis B treatment were approved by the 
(Table 1), and hepatitis B is the underlying cause of an esti-
Food and Drug Administration (FDA) in 2002 or later; two 
mated 2,000–4,000 deaths each year in the United States (6). 
forms of alfa 2 interferon and five oral nucleoside/nucleotide 
Improving the identification and public health management 
analogues have been approved, and other medications are in 
of persons with chronic HBV infection can help prevent seri­
clinical trials.
ous sequelae of chronic liver disease and complement immu-
Serologic testing for hepatitis B surface antigen (HBsAg) is 
nization strategies to eliminate HBV transmission in the 
the primary way to identify persons with chronic HBV infec­
tion. Because of the availability of effective vaccine and 
The material in this report originated in the National Center for HIV/ postexposure prophylaxis, CDC previously recommended 
AIDS, Viral Hepatitis, STD, and TB Prevention, Kevin Fenton, MD, HBsAg testing for pregnant women, infants born to HBsAg-
Director, and the Division of Viral Hepatitis, John Ward, MD, Director. positive mothers, household contacts and sex partners of HBV-
Corresponding preparer: Cindy M. Weinbaum, MD, Division of
 
Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD,
 infected persons, persons born in countries with HBsAg 
and TB Prevention, 1600 Clifton Road, MS G-37, Atlanta GA 30333. prevalence of >8%, and persons who are the source of blood 
Telephone: 404-718-8596; Fax: 404-718-8595; email: chw4@cdc.gov. or body fluid exposures that might warrant postexposure pro­
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TABLE 1. Estimated number and percentage of hepatitis B surface antigen (HBsAg)–positive persons, by population segment — 
United States, 2006 
2006  HBsAg–positive persons 
population HBsAg prevalence No. 
Population segment (millions) (%) (thousands) (%) 
U.S.-born, noninstitutionalized* 254.3 0.1 356 (30–50) 
(95% CI† = 0.1–0.2) (229–534) 
Foreign-born§ 37.5 1.0–2.6 375–975 (47–70) 
Correctional institutions¶ 2.2 2.0 44 (3–5) 
Other group living quarters** 6 0.5 30 (2–3) 
Total 300 0.3–0.5 805–1,405 
* Source: 2006 American Community Survey, U.S. Census Bureau. Excludes persons living in correctional institutions and other group quarters. HBsAg 
prevalence estimates were derived from the National Health and Nutrition Examination Survey (CDC, unpublished data, 2008). 
† Confidence interval. 
§ Sources: 2006 American Community Survey, U.S. Census Bureau. Prevalence range represents estimates from the National Health and Nutrition 
Examination Survey (1%) (CDC, unpublished data, 2008) and country-specific HBsAg estimates reported in the medical literature (2.6%) (CDC, unpub­
lished data, 2008), applied to the estimated population by country of origin. Infant immunization programs in many countries have led to marked 
decreases in incidence and prevalence among younger, vaccinated members of these populations, which are largely not reflected in the medical 
literature (Wasley A, Kruszon-Moran D, Kuhnert W, et al. Hepatitis B prevalence in the U.S. in era of vaccination [Abstract 723]. 45th Annual Meeting of 
the Infectious Diseases Society of America, San Diego, California; October 4–7, 2007). 
¶ Sources: Sabol WJ, Minton TD, Harrison PM. Prison and jail inmates at midyear 2006. Washington, DC: U.S. Department of Justice, Bureau of Justice 
Statistics, Office of Justice Programs; 2007. Available at http://www.ojp.usdoj.gov/bjs/pub/pdf/pjim06.pdf. CDC. Prevention and control of infections 
with hepatitis viruses in correctional settings. MMWR 2003;52(No. RR-1). 
** Includes college dormitories, military quarters, nursing homes, group homes, and long-term care hospitals, as well as homeless persons. For persons 
in other group-living quarters, estimated HBsAg prevalence was assumed to be equal to the mean prevalence in other groups. Source: 2006 American 
Community Survey, U.S. Census Bureau. 
phylaxis (e.g., needlestick injury to a health-care worker or HBV endemicity, and 3) the increasing benefits of care and 
sexual assault), and persons infected with human immunode- opportunities for prevention for infected persons and their 
ficiency virus (HIV) (4,5,7–11). This report updates and contacts. On the basis of this discussion, CDC determined 
expands these multiple previous CDC guidelines for HBsAg that reconsideration of current guidelines was warranted. This 
testing and includes new recommendations for public health report summarizes current HBsAg testing recommendations 
evaluation and management of chronically infected persons published previously by CDC, expands CDC recommenda­
and their contacts. Routine HBsAg testing now is recom- tions to increase the identification of chronically infected 
mended for persons born in geographic regions in which persons in the United States, and defines the components 
HBsAg prevalence is >2%, men who have sex with men of programs needed to identify HBV-infected persons 
(MSM), and injection-drug users (IDUs). successfully. 
Methods Clinical Features and Natural 
During February 7–8, 2007, CDC convened a meeting of History of HBV Infection 
researchers, physicians, state and local public health profes- HBV is a 42-nm DNA virus in the Hepadnaviridae family. 
sionals, and other persons in the public and private sectors After a susceptible person is exposed, the virus is transported 
with expertise in the prevention, care, and treatment of chronic by the bloodstream to the liver, which is the primary site of 
hepatitis B. These consultants reviewed available published HBV replication. HBV infection can produce either asymp­
and unpublished epidemiologic and treatment data, consid­ tomatic or symptomatic infection. When clinical manifesta­
ered whether to recommend testing specific new populations tions of acute disease occur, illness typically begins 2–3 months 
for HBV infection, and discussed how best to implement new after HBV exposure (range: 6 weeks–6 months). Infants, chil­
and existing testing strategies. Topics discussed included dren aged <5 years, and immunosuppressed adults with newly 
1) the changing epidemiology of chronic HBV infection, acquired HBV infection typically are asymptomatic; 30%– 
2) health disparities caused by the disproportionate HBV­ 50% of other persons aged >5 years have clinical signs or symp­
related morbidity and mortality among persons infected as toms of acute disease after infection. Symptoms of acute 
infants and young children in countries with high levels of hepatitis B include fatigue, poor appetite, nausea, vomiting, 
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abdominal pain, low-grade fever, jaundice, dark urine, and 
light stool color. Clinical signs include jaundice, liver tender­
ness, and possibly hepatomegaly or splenomegaly. Fatigue and 
loss of appetite typically precede jaundice by 1–2 weeks. Acute 
illness typically lasts 2–4 months. The case-fatality rate among 
persons with reported cases of acute hepatitis B is approxi­
mately 1%, with the highest rates occurring in adults aged 
>60 years (12). 
Primary HBV infection can be self-limited, with elimina­
tion of virus from blood and subsequent lasting immunity 
against reinfection, or it can progress to chronic infection with 
continuing viral replication in the liver and persistent vire­
mia. Resolved primary infection is not a risk factor for subse­
quent occurrence of chronic liver disease or hepatocellular 
carcinoma (HCC). However, patients with resolved infection 
who become immunosuppressed (e.g., from chemotherapy or 
medication) might, albeit rarely, experience reactivation of 
hepatitis B with symptoms of acute illness (13–15). HBV DNA 
has been detected in the livers of persons without serologic 
markers of chronic infection after resolution of acute infec­
tion (13,16–19). The risk for progression to chronic infec­
tion is related inversely to age at the time of infection. HBV 
infection becomes chronic in >90% of infants, approximately 
25%–50% of children aged 1–5 years, and <5% of older chil­
dren and adults) (13,20–23). Immunosuppressed persons (e.g., 
hemodialysis patients and persons with HIV infection) are at 
increased risk for chronic infection (22). Once chronic HBV 
infection is established, 0.5% of infected persons spontane­
ously resolve infection annually (indicated by the loss of 
detectable HBsAg and serum HBV DNA and normalization 
of serum alanine aminotransferase [ALT] levels); resolution is 
rarer among children than among adults (13,24,25). 
Persons with chronic HBV infection can be asymptomatic 
and have no evidence of liver disease, or they can have a spec­
trum of disease, ranging from chronic hepatitis to cirrhosis or 
liver cancer. Chronic infection is responsible for the majority 
of cases of HBV-related morbidity and mortality; follow-up 
studies have demonstrated that approximately 25% of per­
sons infected with HBV as infants or young children and 15% 
of those infected at older ages died of cirrhosis or liver cancer. 
The majority remained asymptomatic until onset of cirrhosis 
or end-stage liver disease (26). Persons with histologic evi­
dence of chronic hepatitis B (e.g., hepatic inflammation and 
fibrosis) are at higher risk for HCC than HBV-infected per­
sons without such evidence (27). Potential extrahepatic com­
plications of chronic HBV infection include polyarteritis 
nodosa (28,29), membranous glomerulonephritis, and mem­
branoproliferative glomerulonephritis (30). 
Serologic Markers of HBV Infection 
The serologic patterns of chronic HBV infection are varied 
and complex. Antigens and antibodies associated with HBV 
infection include HBsAg and antibody to HBsAg (anti-HBs), 
hepatitis B core antigen (HBcAg) and antibody to HBcAg 
(anti-HBc), and hepatitis B e antigen (HBeAg) and antibody 
to HBeAg (anti-HBe). Testing also can be performed to assess 
the presence and concentration of circulating HBV DNA. At 
least one serologic marker is present during each of the differ­
ent phases of HBV infection (Figures 1 and 2) (31). Serologic 
assays are available commercially for all markers except HBcAg, 
because no free HBcAg circulates in blood. No rapid or oral 
fluid tests are licensed in the United States to test for any 
HBV markers. 
Three phases of chronic HBV infection have been recog­
nized: the immune tolerant phase (HBeAg-positive, with high 
levels of HBV DNA but absence of liver disease), the immune 
active or chronic hepatitis phase (HBeAg-positive, HBeAg­
negative, or anti-HBe-positive, with high levels of HBV DNA 
and active liver inflammation), and the inactive phase (anti-
HBe positive, normal liver aminotransferase levels, and low 
or absent levels of HBV DNA) (32). Patients can evolve 
through these phases or revert from inactive hepatitis B back 
to immune active infection at any time. 
The serologic markers typically used to differentiate among 
acute, resolving, and chronic infection are HBsAg, IgM anti-
HBc, and anti-HBs (Table 2). The presence of HBeAg and 
HBV DNA generally indicates high levels of viral replication; 
FIGURE 1. Typical serologic course of acute hepatitis B virus 
infection with recovery 
Symptoms 
*HBeAg anti-HBe 
Total anti-HBc 
HBsAg 
IgM** anti-HBc 
anti-HBs 
¶ 
§ 
0 4 8 12 16 20 24 28 32 36 52 
Postexposure (wks) 
100 
* Hepatitis B e antigen. 
† Antibody to HBeAg.
 
§ Antibody to hepatitis B core antigen.
 
¶ Hepatitis B surface antigen.
 
** Immunoglobulin M. 
†† Antibody to HBsAg. 
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FIGURE 2. Typical serologic course of acute hepatitis B virus 
(HBV) infection with progression to chronic HBV infection 
Acute (6 mos) Chronic (yrs) 
Total anti-HBc 
HBsAg 
IgM** anti-HBc 
HBeAg anti-HBe 
¶ 
§ 
* 
0 4 8  12  16  20  24  28  32  36  
Postexposure (wks) 
52  Yrs 
* Hepatitis B e antigen. 
† Antibody to HBeAg. 
§ Antibody to hepatitis B core antigen. 
¶ Hepatitis B surface antigen. 
** Immunoglobulin M. 
the presence of anti-HBe usually indicates decreased or unde­
tectable HBV DNA and lower levels of viral replication. 
In newly infected persons, HBsAg is the only serologic 
marker detected during the first 3–5 weeks after infection. 
The average time from exposure to detection of HBsAg is 30 
days (range: 6–60 days) (31,33). Highly sensitive single-sample 
nucleic acid tests can detect HBV DNA in the serum of an 
infected person 10–20 days before detection of HBsAg (34). 
Transient HBsAg positivity has been reported for up to 18 
days after hepatitis B vaccination and is clinically insignifi­
cant (35,36). 
Anti-HBc appears at the onset of symptoms or liver-test 
abnormalities in acute HBV infection and persists for life in 
the majority of persons. Acute or recently acquired infection 
can be distinguished from chronic infection by the presence 
of the immunoglobulin M (IgM) class of anti-HBc, which is 
detected at the onset of acute hepatitis B and persists for up to 
6 months if the infection resolves. In patients with chronic 
HBV infection, IgM anti-HBc can persist during viral repli­
cation at low levels that typically are not detectable by the 
assays used in the United States. However, persons with exac­
erbations of chronic infection can test positive for IgM anti-
HBc (37). Because the positive predictive value of this test is 
low in asymptomatic persons, IgM anti-HBc testing for diag­
nosis of acute hepatitis B should be limited to persons with 
clinical evidence of acute hepatitis or an epidemiologic link to 
a person with HBV infection. 
In persons who recover from HBV infection, HBsAg and 
HBV DNA usually are eliminated from the blood, and anti-
HBs appears. In persons who become chronically infected, 
HBsAg and HBV DNA persist. In persons in whom chronic 
infection resolves, HBsAg becomes undetectable; anti-HBc 
persists and anti-HBs will occur in the majority of these per­
sons (38,39). 
In certain persons, total anti-HBc is the only detectable HBV 
serologic marker. Isolated anti-HBc positivity can represent 
1) resolved HBV infection in persons who have recovered but 
whose anti-HBs levels have waned, most commonly in high-
prevalence populations; 2) chronic infection in which circu­
lating HBsAg is not detectable by commercial serology, most 
commonly in high-prevalence populations and among per­
sons with HIV or HCV infection (40) (HBV DNA has been 
isolated from the blood in <5% of persons with isolated anti-
HBc) (40,41); or 3) false-positive reaction. In low-prevalence 
populations, isolated anti-HBc may be found in 10%–20% 
of persons with serologic markers of HBV infection, most of 
whom will demonstrate a primary response after hepatitis B 
vaccination(42,43). Persons positive only for anti-HBc are 
unlikely to be infectious except under unusual circumstances 
in which they are the source for direct percutaneous exposure 
of susceptible recipients to substantial quantities of virus (e.g., 
blood transfusion or organ transplant) (44). 
HBeAg can be detected in the serum of persons with acute 
or chronic HBV infection. In the majority of those with 
TABLE 2. Typical interpretation of serologic test results for hepatitis B virus infection
 Serologic marker 
HBsAg* Total anti-HBc† IgM§ anti-HBc Anti-HBs¶ Interpretation 
—** — — — Never infected and no evidence of immunization 
+†† + — — Chronic infection 
+ + + — Acute infection 
— + — + Recovered from past infection and immune 
— — — + Immune (immunization or natural) 
* Hepatitis B surface antigen. 
† Antibody to hepatitis B core antigen.
 
§ Immunoglobulin M.
 
¶ Antibody to HBsAg.
 
** Negative test result. 
†† Positive test result. To ensure that an HBsAg-positive test result is not a false positive, samples with repeatedly reactive HBsAg results should be tested 
with a licensed neutralizing confirmatory test. 
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chronic infection, HBeAg is cleared over time, and anti-HBe 
appears (45–49). Presence of HBeAg correlates with more 
active disease: patients with HBeAg typically have high levels 
of HBV DNA (106–1010 IU/mL), whereas those who are 
HBeAg-negative and anti-HBe-positive generally have low or 
only modest HBV DNA levels (0–105 IU/mL). 
Epidemiology of HBV Infection 
in the United States 
Transmission 
HBV is transmitted by percutaneous and mucosal exposure 
to infectious blood or body fluids. The highest concentra­
tions of virus are found in blood; however, semen and saliva 
also have been demonstrated to be infectious (50). HBV 
remains viable and infectious in the environment for at least 7 
days and can be present in high concentrations on inanimate 
objects, even in the absence of visible blood (13,51). Persons 
with chronic HBV infection are the major source of new 
infections, and the primary routes of HBV transmission are 
sexual contact, percutaneous exposure to infectious body flu­
ids (such as occurs through needle sharing by IDUs or 
needlestick injuries in health-care settings), perinatal expo­
sure to an infected mother, and prolonged, close personal con­
tact with an infected person (e.g., via contact with exudates 
from dermatologic lesions, contact with contaminated sur­
faces, or sharing toothbrushes or razors), as occurs in house­
hold contact (5,52). No evidence exists of transmission of HBV 
by casual contact in the workplace, and transmission occurs 
rarely in childcare settings (4). Few cases have been reported 
in which health-care workers have transmitted infection to 
patients, particularly since implementation of standard 
universal infection control precautions (53). 
Incidence of HBV Infection 
During 1985–2006, incidence of acute hepatitis B in the 
United States declined substantially, from 11.5 cases per 
100,000 population in 1985 to 1.6 in 2006 (12). The actual 
incidence of new HBV infections is estimated to be approxi­
mately tenfold higher than the reported incidence of acute 
hepatitis B, after adjustment for underreporting of cases and 
asymptomatic infections. In 2006, an estimated 46,000 per­
sons were newly infected with HBV (54). The greatest 
declines in incidence of acute disease have occurred in the 
cohorts of children for whom infant and adolescent catch-up 
vaccination was recommended (12). Among children aged <15 
years, incidence of hepatitis B declined 98% during 1990– 
2006, from 1.2 per 100,000 population in 1990 to 0.02 in 
2006 (12). This decline reflects the effective implementation 
of hepatitis B vaccination in the United States. Since 2001, 
fewer than 30 cases of acute hepatitis B have been reported 
annually in children born in 1991 or later, the majority of 
whom were international adoptees or children born outside 
the United States who were not fully vaccinated (55). In 2006, 
adults aged >20 years had the highest incidence of acute HBV 
infection, reflecting low hepatitis B vaccination coverage 
among adults with behavioral risks for HBV infection (e.g., 
MSM, IDUs, persons with multiple sex partners, and persons 
whose sex partners are infected with HBV) (12). 
Prevalence of HBV Infection 
and Its Sequelae 
U.S. mortality data for 2000–2003 indicated that HBV 
infection was the underlying cause of an estimated 2,000– 
4,000 deaths annually. The majority of these deaths resulted 
from cirrhosis and liver cancer (6; CDC, unpublished data, 
2000–2003). 
The burden of chronic HBV infection in the United States 
is greater among certain populations as a result of earlier age 
at infection, immune suppression, or higher levels of circulat­
ing infection. These include persons born in geographic 
regions with high (>8%) or intermediate (2%–7%) prevalence 
of chronic HBV infection, HIV-positive persons (who might 
have additional risk factors) (56–58), and certain adult popu­
lations for whom hepatitis B vaccination has been recom­
mended because of behavioral risks (e.g., MSM and IDUs). 
An accurate estimate of the prevalence of chronic HBV infec­
tion in the United States must be derived from multiple sources 
of data to account for the disproportionate contributions of 
persons of foreign birth, members of certain ethnic minority 
populations, and persons with certain medical conditions 
(Table 1). For the U.S.-born civilian noninstitutionalized 
population, prevalence estimates can be obtained from the 
most recent National Health and Nutrition Examination Sur­
vey (NHANES), which was conducted during 1999–2004 
(available at http://www.cdc.gov/nchs/nhanes.htm). Because 
data from studies of foreign-born U.S. residents indicate that 
HBsAg seroprevalence corresponds to HBV endemicity in the 
country of origin (5), for the foreign-born population resid­
ing in the United States, HBV prevalence estimates were 
derived by applying country-specific prevalence estimates gath­
ered from the scientific literature and the World Health 
Organization (2) to the number of foreign-born U.S. resi­
dents by their country of birth as reported by the 2006 U.S. 
Census American Community Survey (59). Other popula­
tions for which estimates were calculated included those in 
correctional institutions and the homeless. Together, these 
6 MMWR September 19, 2008 
sources indicated that an estimated 800,000–1.4 million per­
sons in the United States have chronic HBV infection. 
Approximately 0.3%–0.5% of U.S. residents are chronically 
infected with HBV; 47%–70% of these persons were born in 
other countries (Table 1). 
Global Variation in Prevalence 
of HBV Infection 
HBV transmission patterns and the seroprevalence of 
chronic HBV infection vary markedly worldwide, although 
seroprevalence studies in many countries are limited, and the 
epidemiology of hepatitis B is changing. Approximately 45% 
of persons worldwide live in regions in which HBV is highly 
endemic (i.e., where prevalence of chronic HBV infection is 
>8% among adults and that of resolved or chronic infection 
[i.e., anti-HBc positivity] is >60%) (2) (Figure 3). Histori­
cally, >90% of new infections occurred among infants and 
young children as the result of perinatal or household trans­
mission during early childhood (26). Infant immunization 
programs in many countries have led to marked decreases in 
incidence and prevalence among younger, vaccinated mem­
bers of these populations (60–63). Countries of intermediate 
HBV endemicity (i.e., HBsAg prevalence of 2%–7%) account 
for approximately 43% of the world’s population; in these 
countries, multiple modes of transmission (i.e., perinatal, 
household, sexual, injection-drug use, and health-care–related) 
contribute to the infection burden. Regions of the world with 
high or intermediate prevalence of HBsAg include much of 
Eastern Europe, Asia, Africa, the Middle East, and the Pacific 
Islands (2,4) (Figure 3 and Table 3). In countries of low ende­
micity (i.e., HBsAg prevalence of <2%), the majority of new 
infections occur among adolescents and adults and are attrib­
utable to sexual and injection-drug–use exposures. However, 
in certain areas of low HBV endemicity, prevalence of chronic 
HBV infection is high among indigenous populations born 
before routine infant immunization (Table 3). 
FIGURE 3. Geographic distribution of chronic hepatitis B virus (HBV) infection — worldwide, 2006* 
HBsAg prevalence 
>8% = high 
2%–7% = intermediate 
<2% = low  
* For multiple countries, estimates of prevalence of hepatitis B surface antigen (HBsAg), a marker of chronic HBV infection, are based on limited data 
and might not reflect current prevalence in countries that have implemented childhood hepatitis B vaccination. In addition, HBsAg prevalence might 
vary within countries by subpopulation and locality. 
Source: CDC. Travelers’ health; yellow book. Atlanta, GA: US Department of Health and Human Services, CDC; 2008. Available at http://wwwn.cdc.gov/ 
travel/yellowbookch4-HepB.aspx. 
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TABLE 3. Geographic regions* with hepatitis B surface antigen (HBsAg) prevalence of >2%† 
Region* HBsAg prevalence >2% 
Africa All countries 
Asia§ All countries 
Australia and South Pacific All countries except Australia and New Zealand 
Middle East All countries except Cyprus and Israel 
Eastern Europe All countries except Hungary 
Western Europe Malta, Spain, and indigenous populations in Greenland 
North America Alaska Natives and indigenous populations in Northern Canada 
Mexico and Central America Guatemala and Honduras 
South America Ecuador, Guyana, Suriname, Venezuela, and Amazonian areas of Bolivia, Brazil, Columbia, and Peru 
Caribbean Antigua-Barbuda, Dominica, Grenada, Haiti, Jamaica, St. Kitts-Nevis, St. Lucia, and Turks and Caicos Islands 
* A complete list of countries in each region is available at http://wwwn.cdc.gov/travel/destinationList.htm. 
†Estimates of prevalence of HBsAg, a marker of chronic hepatitis B virus infection, are based on limited data and might not reflect current prevalence in 
countries that have implemented childhood hepatitis B vaccination. In addition, HBsAg prevalence might vary within countries by subpopulation and 
locality. 
§Asia includes three regions: Southeast Asia, East Asia, and Northern Asia. 
In the United States, marked decreases in the prevalence of 
chronic HBV infection among younger, vaccinated foreign-
born U.S. residents have been observed, most likely as a result 
of infant immunization programs globally (64). However, the 
rate of liver cancer deaths in the United States continues to be 
high among certain foreign-born U.S. populations. For 
example, the rate of liver cancer deaths is highest among Asians/ 
Pacific Islanders, reflecting the high prevalence of chronic 
hepatitis B in this population (65,66). Globally, other regions 
with HBsAg prevalence of >2% also have identified high lev­
els of HBV-associated HCC (67,68). 
Household Contacts and Sex Partners 
of Persons With Chronic HBV Infection 
Serologic testing and hepatitis B vaccination has been rec­
ommended since 1982 (69) for household contacts and sex 
partners of persons with chronic HBV infection because pre­
vious studies have determined that 14%–60% of persons liv­
ing in households with persons with chronic HBV infection 
have serologic evidence indicating resolved HBV infection, 
and 3%–20% have evidence indicating chronic infection. The 
risk for infection is highest among unvaccinated children liv­
ing with a person with chronic HBV infection in a household 
or in an extended family setting and among sex partners of 
chronically infected persons (70–77). 
Men Who Have Sex With Men 
During 1994–2000, studies of MSM aged <30 years iden­
tified chronic infection in 1.1% of MSM aged 18–24 years 
(95% confidence interval [CI] = 0–2.2%) (78), 2.1% (95% 
CI = 1.6%–2.6%) of MSM aged 15–21 years (79), and 2.3% 
(95% CI = 1.7%–2.8%) of MSM aged 22–29 years (80). In 
these studies, prevalence was higher (7.4%; 95% CI = 5.3%– 
9.6%) among young MSM who were HIV-positive than it 
was among those who were HIV-negative (1.5%; 95% CI = 
1.2%–1.9%) (CDC, unpublished data, 2007). Before the 
introduction of the hepatitis B vaccine in 1982, prevalence of 
chronic HBV infection among MSM was 4.6%–6.1% (81– 
83). In recent studies, prevalence of past infection increased 
with increasing age, suggesting that chronic infection might 
still be more prevalent among older MSM (79,80). 
Injection-Drug Users 
Chronic HBV infection has been identified in 2.7%–11.0% 
of IDUs in a variety of settings (84–91); HBsAg prevalence of 
7.1% (95% CI = 6.3%–7.8%) has been described among IDUs 
with HIV coinfection (92). IDUs contribute disproportion­
ately to the burden of infection in the United States: in chronic 
HBV infection registries, 4%–12% of reported chronically 
infected persons had a history of injection-drug use (93). Preva­
lence of resolved or chronic HBV infection among IDUs 
increases with the number of years of drug use and is associ­
ated with frequency of injection and with sharing of drug-
preparation equipment (e.g., cottons, cookers, and rinse water), 
independent of syringe sharing (94,95). 
HIV-Positive Persons 
As life expectancies for HIV-infected persons have increased 
with use of highly active antiretroviral therapy, liver disease, 
much of it related to HBV and HCV infections, has become 
the most common non-AIDS–related cause of death among 
this population (56,57,96,97). Chronic HBV infection has 
been identified in 6%–15% of HIV-positive persons from 
Western Europe and the United States, including 9%–17% 
of MSM; 7%–10% of IDUs; 4%–6% of heterosexuals; and 
1.5% of pregnant women (58,98,99). This high level of 
chronic infection reflects both common routes of transmis­
sion for HIV and HBV and a higher risk of chronicity after 
HBV infection in an immunocompromised host (100–102). 
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Persons With Selected Medical Conditions 
Although population-level studies are lacking to determine 
HBsAg prevalence among populations with other medical 
conditions, persons with chronic HBV infection who initiate 
cytotoxic or immunosuppressive therapy (e.g., chemotherapy 
for malignant diseases, immunosuppression related to organ 
transplantation, and immunosuppression for rheumatologic 
and gastroenterologic disorders) are at risk for HBV reactiva­
tion and associated morbidity and mortality (32,101,102). 
Prophylactic antiviral therapy can prevent reactivation and 
possible fulminant hepatitis in HBsAg positive patients 
(13,101). 
Rationale for Testing to Identify 
Persons With Chronic HBV Infection 
Although limited data are available regarding the number of 
persons with chronic HBV infection in the United States who 
are unaware of their infection status, studies of programs con­
ducting HBsAg testing among Asian-born persons living in the 
United States indicated that approximately one third of infected 
persons were unaware of their HBV infection (5,103–105). 
Published studies for other populations are lacking. Prompt 
identification of chronic infection with HBV is essential to 
ensure that infected persons receive necessary care to prevent or 
delay onset of liver disease and services to prevent transmission 
to others. Treatment guidelines for chronic hepatitis B have been 
issued (13,106,107), and multiple medications have been 
approved for treatment of adults with chronic HBV infection. 
With recent advances in hepatitis B treatment and detection of 
liver cancer, identification of an HBV-infected person permits 
the implementation of important interventions to reduce mor­
bidity and mortality, including 
• clinical evaluations to detect onset and progression of 
HBV-related liver disease; 
• antiviral treatment for chronic HBV infection, which can 
delay or reverse the progression of liver disease (13); 
• baseline AFP measurement and periodic ultrasound sur­
veillance to detect HCC at a potentially treatable stage 
because early intervention to ablate small localized tumors, 
resect, or transplant has resulted in long-term tumor-free 
survival (108); and 
• interventions designed to reduce progression of liver injury, 
including vaccination against hepatitis A and counseling 
to avoid excessive alcohol use. Morbidity and mortality 
from hepatitis A are increased in the presence of chronic 
liver disease (109); alcohol use of >25mL–30mL/day is 
associated with progression of HBV-related liver disease 
(110,111). 
Identification of infected persons also allows for primary 
prevention of ongoing HBV transmission by enabling per­
sons with chronic infection to adopt behaviors that reduce 
the risk of transmission to others and by permitting identifi­
cation of close contacts who require testing and subsequent 
vaccination (if identified as susceptible) or medical manage­
ment (if identified as having chronic HBV infection). Appro­
priate HBsAg testing and counseling also help prevent 
health-care–associated transmission in dialysis settings by 
allowing for cohorting of infected patients (112). Testing 
donated blood and donors of organs and tissues prevents 
infectious materials from being used and allows unvaccinated 
persons exposed to needlesticks to receive additional 
postexposure prophylaxis if the source of the exposure was 
HBV-infected (113). 
Testing for chronic HBV infection meets established public 
health screening criteria (114). Screening is a basic public 
health tool used to identify unrecognized health conditions 
so treatment can be offered before symptoms occur and, for 
communicable diseases, so interventions can be implemented 
to reduce the likelihood of continued transmission (114). 
Screening for chronic HBV infection is consistent with the 
main generally accepted public health screening criteria: 
1) chronic hepatitis B is a serious health disorder that can be 
diagnosed before symptoms occur; 2) it can be detected by 
reliable, inexpensive, and minimally invasive screening tests; 
3) chronically infected patients have years of life to gain if 
medical evaluation and/or treatment is initiated early, before 
symptoms occur; and 4) the costs of screening are reasonable 
in relation to the anticipated benefits (114). The cost-
effectiveness of identifying persons with chronic HBV infec­
tion cannot be calculated because treatment options constantly 
are increasing the number of years of disease-free life, and the 
various treatments have diverse associated costs. However, test­
ing for HBsAg in populations in which prevalence of chronic 
infection is 2% would cost $750–$3,752 for each chronically 
infected person identified (range represents $15.01 labora­
tory cost per test–$75 per screening visit [Marketscan® Data­
base, Ann Arbor, Michigan, unpublished data, 2007]); at 
higher prevalences, the per-case-identified cost would decrease. 
This is comparable to the cost of other screening programs. 
HIV testing in a population with 1% infection prevalence 
costs $2,133 ([$1,733–$3,733] per positive identified (115); 
[Marketscan® Database, Ann Arbor, Michigan, unpublished 
data, 2007] $16 per test [$13–$28]). Another study deter­
mined that the cost to identify each new case of diabetes mel­
litus using a two-step glucose-based screening process in three 
volunteer clinics in Minnesota was $4,064 per case identified 
(116). The cost of HBsAg testing in populations with >2% 
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prevalence is substantially lower than the costs per case iden­
tified for certain fetal and newborn screening interventions 
(e.g., screening for newborn hearing disorders [$16,000 per 
case identified] [117], metabolic disorders [$68,000 per case] 
[118], neonatal alloimmune thrombocytopenia [NAIT] 
caused by anti-HPA-1a [$98,771 per case] [119], or fetal 
Down syndrome [$690,000 per case] [120]). 
To prevent HBV transmission, previous guidelines have rec­
ommended HBsAg testing for hemodialysis patients, preg­
nant women, and persons known or suspected of having been 
exposed to HBV (i.e., infants born to HBV-infected mothers, 
household contacts and sex partners of infected persons, and 
persons with known occupational or other exposures to infec­
tious blood or body fluids) (3,112). HBsAg testing also is 
required for donors of blood, organs, and tissues (113). To guide 
immunization efforts and identify infected persons, testing also 
has been recommended previously for persons born in regions 
with high HBV endemicity (4,121). Finally, testing has been 
recommended for HIV-positive persons on the basis of their 
high prevalence of HBV coinfection and their increased risk for 
HBV-associated morbidity and mortality (122). 
Because persons with chronic HBV infection serve as the 
reservoir for new HBV infections in the United States, identi­
fication of these persons will complement vaccination strate­
gies for elimination of HBV transmission. With the availability 
of effective treatments for chronic hepatitis B, the infected 
person, once identified, can benefit from testing as well. Thus, 
CDC recommends expanding HBV testing to include all per­
sons born in regions with HBsAg prevalence of >2% (high 
and intermediate endemicity). CDC also recommends HBsAg 
testing in addition to vaccination for MSM and IDUs 
because of their higher-than-population prevalence and their 
ongoing risk for infection. Finally, to prevent adverse medical 
outcomes among persons who might be seeking medical care 
for other reasons, recommendations also are made to test per­
sons with ALT elevations of unknown etiology and candi­
dates for immunosuppressive therapies. 
Recommendations 
Persons who are most likely to be actively infected with HBV 
should be tested for chronic HBV infection. Testing should 
include a serologic assay for HBsAg offered as a part of rou­
tine care and be accompanied by appropriate counseling 
and referral for recommended clinical evaluation and care. 
Laboratories that provide HBsAg testing should use an FDA-
licensed or FDA-approved HBsAg test and should perform 
testing according to the manufacturer’s labeling, including test­
ing of initially reactive specimens with a licensed, neutralizing 
confirmatory test. A confirmed HBsAg-positive result indi­
cates active HBV infection, either acute or chronic; chronic 
infection is confirmed by the absence of IgM anti-HBc or by 
the persistence of HBsAg or HBV DNA for at least 6 months. 
All HBsAg-positive persons should be considered infectious. 
Recommendations and federal mandates related to routine 
testing for chronic HBV infection have been summarized 
(Table 4). To determine susceptibility among persons who are 
at ongoing risk for infection and recommended for vaccina­
tion, total anti-HBc or anti-HBs also should be tested at the 
time of serologic testing for chronic HBV infection. New 
populations recommended for testing are the following: 
•	 Persons born in geographic regions with HBsAg preva­
lence of >2%. All persons born in geographic regions with 
HBsAg prevalence of >2% (e.g., much of Eastern Europe, 
Asia, Africa, the Middle East, and the Pacific Islands) 
(Figure 3 and Table 3) and certain indigenous populations 
from countries with overall low HBV endemicity (<2%) 
(Table 3) should be tested for chronic HBV infection. This 
includes immigrants, refugees, asylum seekers, and inter­
nationally adopted children born in these regions, regard­
less of vaccination status in their country of origin (123). 
Medical screening of applicants for lawful permanent resi­
dency in the United States represents an opportunity for 
education and voluntary HBsAg testing. Because HBsAg 
prevalence can vary within these regions, additional knowl­
edge about local HBsAg prevalence can be used to guide deci­
sion making regarding testing. 
•	 Persons with behavioral exposures to HBV. MSM and 
past or current IDUs have higher prevalence of chronic 
HBV infection than the overall U.S. population (Table 5) 
and should be tested for chronic HBV infection. Both of 
these populations are recommended for routine hepatitis 
B vaccination (5), and HBsAg testing is recommended as 
a component of prevaccination testing for these adults. 
The first dose of hepatitis B vaccine should be adminis­
tered during the same medical visit with serologic testing. 
However, HBsAg testing is not a requirement for vacci­
nation, and in settings where testing is not feasible, vacci­
nation of recommended populations should continue. 
•	 Persons receiving cytotoxic or immunosuppressive 
therapy. Persons receiving cytotoxic or immunosuppres­
sive therapy (e.g., chemotherapy for malignant diseases, 
immunosuppression related to organ transplantation, and 
immunosuppression for rheumatologic and gastroenter­
ologic disorders) should be tested for serologic markers of 
HBV infection (i.e., HBsAg, anti-HBc, and anti-HBs). 
Prophylactic antiviral therapy can prevent reactivation in 
HBsAg-positive patients (13,101). 
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TABLE 4. Populations recommended or required for routine testing for chronic hepatitis B virus (HBV) infection 
Population Population-specific testing consideration Source 
Persons born in regions of high 
and intermediate HBV endemicity 
(HBsAg* prevalence >2%)† 
U.S.-born persons not vaccinated 
as infants whose parents were 
born in regions with high HBV 
endemicity (>8%) 
Injection-drug users 
Men who have sex with men 
Persons needing immunosuppres­
sive therapy, including chemo­
therapy, immunosuppression 
related to organ transplantation, 
and immunosuppression for 
rheumatologic or gastroenterologic 
disorders 
Persons with elevated ALT/AST§§ 
of unknown etiology 
Donors of blood, plasma, organs, 
tissues, or semen 
Hemodialysis patients 
All pregnant women 
Infants born to HBsAg-positive 
mothers 
All persons (including immigrants, refugees, asylum seekers, and 
internationally adopted children) born in regions with high and 
intermediate endemicity of HBV infection should be tested for 
HBsAg, regardless of vaccination status in their country of origin. 
If not vaccinated as infants in the United States, these persons 
should be tested regardless of maternal HBsAg status. 
• First vaccine dose should be given at the same visit as testing 
for HBsAg.§ 
• Testing for anti-HBc¶ or anti-HBs** should be done as well to 
identify susceptible persons.†† 
• Susceptible persons should complete a 3-dose hepatitis B 
vaccine series to prevent infection from ongoing exposure. 
• First vaccine dose should be given at the same visit as testing 
for HBsAg. 
• Testing for anti-HBc or anti-HBs should be done as well to 
identify susceptible persons. 
• Susceptible persons should complete a 3-dose hepatitis B 
vaccine series to prevent transmission from ongoing exposure. 
• Serologic testing should test for all markers of HBV infection 
(HBsAg, anti-HBc, and anti-HBs). 
• Because of elevated risk of fulminant hepatitis in chronically 
infected persons once suppressive therapy is initiated and risk 
for reactivation in persons with resolved infection, persons who 
are HBsAg-positive should be treated, and persons who are 
anti-HBc positive should be monitored closely for signs of liver 
disease. 
• Testing for HBsAg should be performed along with other 
examination and laboratory testing in the context of medical 
evaluation. 
• To prevent transmission to recipients, HBsAg, anti-HBc, and 
HBV-DNA testing are required. 
• Serologic testing should test for all markers of HBV infection 
(HBsAg, anti-HBc, and anti-HBs) on admission. 
• To prevent transmission in dialysis settings, hemodialysis 
patients should be vaccinated against hepatitis B and 
revaccinated when serum anti-HBs titer falls below 10mIU/mL. 
• HBsAg-positive hemodialysis patients should be cohorted. 
• Vaccine nonresponders should be tested monthly for HBsAg. 
• Women should be tested for HBsAg during each pregnancy, 
preferably in the first trimester. 
• If an HBsAg test result is not available or if the mother was 
at risk for infection during pregnancy, testing should be 
performed at the time of admission for delivery. 
• To prevent perinatal transmission, infants of HBsAg-positive 
mothers and unknown HBsAg status mothers should 
receive vaccination and postexposure immunoprophylaxis 
in accordance with recommendations within 12 hours 
of delivery. 
• Testing for HBsAg and anti-HBs should be performed 1–2 mos 
after completion of at least 3 doses of a licensed hepatitis B 
vaccine series (i.e., at age 9–18 months, generally at the next 
well-child visit) to assess the effectiveness of postexposure 
immunoprophylaxis. Testing should not be performed before age 
9 months or within 1 month of the most recent vaccine dose. 
• Maternal and infant medical records should be reviewed to 
determine whether infant received hepatitis B immune globulin 
and vaccine in accordance with recommendations. 
• CDC. A comprehensive immunization strategy to eliminate 
transmission of hepatitis B virus infection in the United 
States: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). Part 1: immunization of 
infants, children, and adolescents. MMWR 2005;54(No. 
RR-16) (for persons from regions with HBsAg prevalence 
of >8%). 
• New recommendation (for persons from regions with HBsAg 
prevalence >2%). 
New recommendation. 
New recommendation. 
New recommendation. 
New recommendation. 
New recommendation. 
Code of Federal Regulations. Title 21. Food and Drugs. 
Part 610.40. 
CDC. Recommendations for preventing transmission of 
infections among chronic hemodialysis patients. MMWR 
2001;50(No. RR-5). 
CDC. A comprehensive immunization strategy to eliminate 
transmission of hepatitis B virus infection in the United States: 
recommendations of the Advisory Committee on Immunization 
Practices (ACIP). Part 1: immunization of infants, children, and 
adolescents. MMWR 2005;54(No. RR-16). 
CDC. A comprehensive immunization strategy to eliminate 
transmission of hepatitis B virus infection in the United States: 
recommendations of the Advisory Committee on Immunization 
Practices (ACIP). Part 1: immunization of infants, children, 
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Goal and Ojectives 
This report updates and expands previous CDC guidelines for hepatitis B surface antigen (HBsAg) testing to identify persons with chronic hepatitis B virus (HBV) 
infection. The report recommends new populations for HBsAg testing and provides new guidelines regarding evaluation and public health management of 
chronically infected persons. The goal of this report is to guide health-care professionals and public health officials in identifying persons with chronic HBV infection 
and ensuring appropriate public health management of these persons and their contacts. Upon completion of this educational activity, the reader should be able to 
1) identify populations for whom routine HBsAg testing is recommended, 2) identify geographic regions with intermediate or high endemicity of HBV infection, 
3) describe components of public health management for HBsAg-positive persons, and 4) describe strategies to increase implementation of HBsAg testing 
recommendations. 
To receive continuing education credit, please answer all of the following questions. 
1.	 For which of the following populations is routine HBsAg testing 
recommended? (Indicate all that apply.) 
A.	 Persons born in regions with high HBV endemicity (i.e., HBsAg 
seroprevalence of >8%). 
B.	 Persons born in regions with intermediate HBV endemicity (i.e., 
HBsAg seroprevalence of 2%–7%). 
C.	 Men who have sex with men (MSM). 
D. Injection-drug users (IDUs). 
E.	 Pregnant women. 
F.	 Sex partners and household contacts of HBsAg-positive persons. 
G. All of the above. 
2.	 Which of the following statements regarding hepatitis B serologic 
testing are true? (Indicate all that apply.) 
A.	 The finding of HBsAg in serum is usually indicative of acute HBV 
infection. 
B.	 To determine susceptibility among persons at ongoing risk for HBV 
infection and for whom hepatitis B vaccination is recommended, 
serologic testing should assess for the presence of anti-HBc or anti-HBs 
in addition to HBsAg. 
C.	 Chronic HBV infection can be confirmed by the persistence of HBsAg 
or HBV DNA for at least 6 months. 
D. The presence of anti-HBe in serum indicates high levels of viral 
replication. 
E.	 All of the above. 
3.	 Which of the following geographic areas have intermediate or high 
endemicity of HBV infection (i.e., HBsAg prevalence of >2%)? 
(Indicate all that apply.) 
A.	 South East Asia. 
B.	 The Pacific Islands. 
C.	 Sub-Saharan Africa. 
D. Australia. 
E.	 Western Europe. 
4.	 In countries with high HBV endemicity, the majority of HBV 
infections occur among infants and young children. 
A.	 True. 
B.	 False. 
5.	 Which of the following statements regarding HBsAg testing 
recommendations are true? (Indicate all that apply.) 
A.	 HBsAg testing is recommended for persons born in HBV-endemic 
countries who were vaccinated against hepatitis B in their country of 
origin. 
B.	 U.S.-born MSM and IDUs who completed the hepatitis B vaccine 
series as infants do not need to be tested for HBsAg. 
C.	 HBsAg testing is recommended for immunosuppressive or cytotoxic 
therapy candidates. 
D. All of the above. 
6.	 For persons with ongoing behavioral risk factors for HBV infection, 
hepatitis B vaccination should be delayed until HBsAg test results are 
obtained. 
A.	 True. 
B.	 False. 
7.	 Identification of HBsAg-positive persons permits which of the 
following? (Indicate all that apply.) 
A.	 Referral of chronically infected persons for medical evaluation and 
monitoring. 
B.	 Identification and vaccination of susceptible sex partners and 
household contacts. 
C.	 Documentation necessary for reporting to the National Chronic 
Hepatitis B Registry. 
D. The opportunity to tailor medical care for patients receiving 
immunosuppressive therapy to prevent reactivation of HBV infection. 
E.	 The opportunity to protect newborns of HBsAg-positive mothers by 
administering hepatitis B immune globulin and hepatitis B vaccine 
beginning at birth. 
8.	 Which of the following patient education messages are recommended 
for HBsAg-positive persons? (Indicate all that apply.) 
A.	 Persons with chronic HBV infection should avoid or limit alcohol 
consumption. 
B.	 When seeking medical or dental care, HBsAg-positive persons should 
inform those responsible for their care of their HBsAg status so they 
can be evaluated and their care managed appropriately. 
C.	 HBsAg-positive persons should use methods (e.g., condoms) to 
protect nonimmune sex partners from acquiring HBV infection until 
the sex partners can be vaccinated and their immunity documented. 
D. HBsAg-positive persons should be advised to cover cuts and lesions to 
avoid spreading infectious blood or secretions to others. 
E.	 All of the above. 
9.	 The majority of state health departments have implemented programs 
to identify persons with chronic HBV infection, provide case 
management, and refer patients for care. 
A.	 True. 
B.	 False. 
10. Which best describes your professional activities? 
A.	 Physician. 
B.	 Nurse. 
C.	 Health educator. 
D. Office staff. 
E.	 Other. 
11. I plan to use these recommendations as the basis for …(Indicate all 
that apply.) 
A.	 health education materials. 
B.	 insurance reimbursement policies. 
C.	 local practice guidelines. 
D. public policy. 
E.	 other. 
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12. Overall, the length of the journal report was… 16. After reading this report, I am confident I describe strategies to 
increase implementation of HBsAg testing recommendations.A. much too long. 
B. a little too long. A. Strongly agree. 
C. just right. B. Agree. 
D. a little too short. C. Undecided. 
E. much too short. D. Disagree. 
E. Strongly disagree.
13. After reading this report, I am confident I can identify populations for 
whom routine HBsAg testing is recommended. 17. The learning outcomes (objectives) were relevant to the goals of this 
report.A. Strongly agree. 
B. Agree. A. Strongly agree. 
C. Undecided. B. Agree. 
D. Disagree. C. Undecided. 
E. Strongly disagree. D. Disagree. 
E. Strongly disagree.
14. After reading this report, I am confident I can identify geographic 
regions with intermediate or high endemicity of HBV infection. 18. The instructional strategies used in this report (text, tables, and 
figures) helped me learn the material.A. Strongly agree. 
B. Agree. A. Strongly agree. 
C. Undecided. B. Agree. 
D. Disagree. C. Undecided. 
E. Strongly disagree. D. Disagree. 
E. Strongly disagree.
15. After reading this report, I am confident I can describe components of 
public health management for HBsAg-positive persons. 19. The content was appropriate given the stated objectives of the report. 
A. Strongly agree. A. Strongly agree. 
B. Agree. B. Agree. 
C. Undecided. C. Undecided. 
D. Disagree. D. Disagree. 
E. Strongly disagree. E. Strongly disagree. 
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20. The content expert(s) demonstrated expertise in the subject matter. 
A. Strongly agree. 
B. Agree. 
C. Undecided. 
D. Disagree. 
E. Strongly disagree. 
21. Overall, the quality of the journal report was excellent. 
A. Strongly agree. 
B. Agree. 
C. Undecided. 
D. Disagree. 
E. Strongly disagree. 
22. These recommendations will improve the quality of my practice. 
A. Strongly agree. 
B. Agree. 
C. Undecided. 
D. Disagree. 
E. Strongly disagree. 
23. The availability of continuing education credit influenced my 
decision to read this report. 
A. Strongly agree. 
B. Agree. 
C. Undecided. 
D. Disagree. 
E. Strongly disagree. 
24. The MMWR format was conducive to learning this content. 
A. Strongly agree. 
B. Agree. 
C. Undecided. 
D. Disagree. 
E. Strongly disagree. 
25. Do you feel this course was commercially biased? (Indicate yes or no; 
if yes, please explain in the space provided.) 
A. Yes. 
B. No. 
26. How did you learn about the continuing education activity? 
A. Internet. 
B. Advertisement (e.g., fact sheet, MMWR cover, newsletter, or journal). 
C. Coworker/supervisor. 
D. Conference presentation. 
E. MMWR subscription. 
F. Other. 
Correct answers for questions 1–9. 1. G; 2. B and C; 3. A, B, and C; 4. 
A; 5. D; 6. B; 7. A, B, D, and E; 8. E; and 9. B. 
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TABLE 4. (Continued ) Populations recommended or required for routine testing for chronic hepatitis B virus (HBV) infection 
Population Population-specific testing consideration Source 
Household,needle-sharing, or sex 
contacts of persons known to be 
HBsAg positive 
Persons who are the sources of 
blood or body fluids for exposures 
that might require postexposure 
prophylaxis (e.g., needlestick, 
sexual assault) 
HIV-positive persons 
• First vaccine dose should be administered at the same visit as 
testing for HBsAg. 
• Testing for anti-HBc or anti-HBs should be performed as well to 
identify susceptible persons. 
• Susceptible persons should complete a 3-dose hepatitis B 
vaccine series to prevent transmission from ongoing exposure. 
• Test source person for HBsAg and provide exposed person 
with postexposure prophylaxis if needed. 
• High levels of vaccination coverage among health-care workers 
have led to marked decreases in hepatitis B incidence. Health-
care and public safety workers with reasonably anticipated 
occupational exposures to blood or infectious body fluids 
should be vaccinated against hepatitis B. 
• Test for HBsAg and anti-HBc and/or anti-HBs. 
• Susceptible persons should be vaccinated against hepatitis B to 
prevent transmission from ongoing exposure. 
• HIV infection can accelerate progression of HBV-related liver 
disease. 
• Antiretroviral medications used to treat HIV infection also have 
anti-HBV activity. Medical regimens for HIV management can 
be tailored according to patient HBV status. 
CDC. A comprehensive immunization strategy to eliminate 
transmission of hepatitis B virus infection in the United States: 
recommendations of the Advisory Committee on Immunization 
Practices (ACIP). Part 1: immunization of infants, children, and 
adolescents. MMWR 2005;54(No. RR-16). 
CDC. Updated U.S. Public Health Service guidelines for the 
management of occupational exposures to HBV, HCV, and 
HIV and recommendations for postexposure prophylaxis. 
MMWR 2001;50(No. RR-11). 
CDC. Treating opportunistic infections among HIV-infected 
adults and adolescents: recommendations from CDC, 
the National Institutes of Health, and the HIV Medicine 
Association/Infectious Diseases Society of America. MMWR 
2004;53(No. RR-15). 
* Hepatitis B surface antigen. 
† High endemicity = HBsAg prevalence of >8%; intermediate endemicity = HBsAg prevalence of 2%–7%. 
§ Unless an established patient-provider relation can ensure that the patient will return for serologic test results and that vaccination can be initiated at that time if the patient 
is susceptible. 
¶ Antibody to hepatitis B core antigen. 
** Antibody to HBsAg. 
†† Persons lacking immunity, either vaccine-induced or following resolved infection, to HBV infection. 
§§ ALT = alanine aminotransferase; AST = aspartate aminotransferase. 
•	 Persons with liver disease of unknown eiology. All per­
sons with persistently elevated ALT or aspartate amino­
transferase (AST) levels of unknown etiology should be 
tested for HBsAg as part of the medical evaluation of 
these abnormal laboratory values. 
Testing Persons With a History 
of Vaccination 
Because some persons might have been infected with HBV 
before they received hepatitis B vaccination, HBsAg testing is 
recommended regardless of vaccination history for the 
following populations: 
•	 Persons born in geographic regions with HBV preva­
lence of >2%. The majority of these persons were born 
either before full implementation of routine infant hepa­
titis B vaccination in their countries of origin or during a 
period when newborn vaccination programs were in the 
early stages of implementation. Because of the difficulty 
in verifying the vaccination status of foreign-born per­
sons and the high rate of perinatal and early childhood 
HBV transmission before implementation of routine 
infant hepatitis B vaccination programs, HBsAg testing 
is recommended for all persons born in regions with high 
or intermediate endemicity of HBV infection even if they 
were vaccinated in their country of origin. 
•	 U.S.-born persons not vaccinated as infants whose 
parents were born in regions with high HBV ende­
micity (>8%). Because of the high efficacy of hepatitis B 
vaccination, persons with HBsAg-negative mothers who 
completed the vaccine series as infants in the United States 
do not need to be tested for HBsAg. However, persons 
vaccinated through catch-up programs as children or ado­
lescents also should be tested if they were likely to have 
had HBV exposures before vaccination. Prevalence of 
chronic HBV infection is high among U.S.-born chil­
dren who were not vaccinated as infants and whose par­
ents were born in regions with high HBV endemicity. 
•	 Persons who received hepatitis B vaccination as ado­
lescents or adults after the initiation of risk behaviors. 
MSM and IDUs who were potentially exposed to HBV 
(e.g., through sexual activity or injection-drug use) 
before vaccination should be tested for HBsAg. 
Management of Persons Tested 
for Chronic HBV Infection 
Vaccination at the Time of Testing 
Persons to be tested who have been recommended to 
receive hepatitis B vaccination, including those in settings in 
which universal vaccination is recommended (i.e., sexually 
12 MMWR September 19, 2008 
TABLE 5. Prevalence of hepatitis B virus (HBV) infection, by U.S. population group 
Chronically infected with HBV* Ever infected with HBV† 
Population (%) (%) 
General§ 0.3 4.8 
(95% CI¶ = 0.2–0.4) (95% CI = 4.2–5.5) 
HIV**-positive persons†† 4–17 24–76 
Injection-drug users§§ 3–6 20–70 
Men who have sex with men¶¶ 1–3 10–40 
Sexual contacts of HBsAg+ persons*** 3.5–9 25–59 
Household contacts of persons with chronic HBV infection††† 3–20 15–60 
* Hepatitis B surface antigen–positive. 
† Antibody to hepatitis B core antigen–positive; includes persons with resolved and chronic infections.
 
§ Source: Estimates were derived from the National Health and Nutrition Examination Survey (CDC, unpublished data, 1999–2002).
 
¶ Confidence interval.
 
** Human immunodeficiency virus. 
†† Source: Alter, MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44(1 Suppl):S6–9. 
§§ Sources: Lopez-Zetina J, Kerndt P, Ford W, Woerhle T, Weber M. Prevalence of HIV and hepatitis B and self-reported injection risk behavior during 
detention among street-recruited injection drug users in Los Angeles County, 1994–1996. Addiction 2001;96:589–95; Des Jarlais DC, Diaz T, Perlis T, 
et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users 
in New York City. Am J Epidemiol 2003;157:467–71; Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection 
drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655– 
61; Kunches LM, Craven DE, Werner BG. Seroprevalence of hepatitis B virus and delta agent in parenteral drug abusers. Immunogenicity of hepatitis 
B vaccine. Am J Med 1986;81:591–5; Raimondo G, Smedile A, Gallo L, Balbo A, Ponzetto A, Rizzetto M. Multicentre study of prevalence of HBV-
associated delta infection and liver disease in drug-addicts. Lancet 1982;1:249–51; Zeldis JB, Jain S, Kuramoto IK, et al. Seroepidemiology of viral 
infections among intravenous drug users in northern California. West J Med 1992;156:30–5; Mangla JC, Kim YM, Brown MR, Schwob D, Hanson SE. 
Liver tests, HB-Ag and HB-Ab in asymptomatic drug addicts. Am J Gastroenterol 1976;65:121–6; Seeff LB, Zimmerman HJ, Wright EC, et al. Hepatic 
disease in asymptomatic parenteral narcotic drug abusers: a Veterans Administration collaborative study. Am J Med Sci 1975;270:41–7; Cherubin CE, 
Schaefer RA, Rosenthal WS, et al. The natural history of liver disease in former drug users. Am J Med Sci 1976;272:244–53; Blanck RR, Ream N, 
Conrad M. Hepatitis B antigen and antibody in heroin users. Am J Gastroenterol 1979;71:164–7; Kellerman SE, Hanson DL, McNaghten AD, Fleming 
PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 
2003;188:571–7; Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and 
C viruses. Am J Epidemiol 1999;149:203–13; Kuo I, Sherman SG, Thomas DL, Strathdee SA. Hepatitis B virus infection and vaccination among young 
injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend 2004;73:69–78. 
¶¶ Source: Weinbaum CM, Rob Lyerla R, MacKellar DA, et al. The Young Men’s Survey phase II: hepatitis B immunization and infection among young 
men who have sex with men. Am J Public Health 2008;98:839–45. 
*** Sources: Heathcote J, Gateau P, Sherlock S. Role of hepatitis-B antigen carriers in non-parenteral transmission of the hepatitis-B virus. Lancet 
1974;2:370–1; Bernier RH, Sampliner R, Gerety R, Tabor E, Hamilton F, Nathanson N. Hepatitis B infection in households of chronic carriers of hepatitis 
B surface antigen: factors associated with prevalence of infection. Am J Epidemiol 1982;116:199–211; Irwin GR, Allen AM, Bancroft WH, Karwacki JJ, 
Pinkerton RH, Russell PK. Hepatitis B antigen and antibody. Occurrence in families of asymptomatic HB AG carriers. JAMA 1974;227:1042–3. 
†††Sources: Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. 
Pediatrics 1992;89:269–73; Mahoney FJ, Lawrence M, Scott C, Le Q, Lambert S, Farley TA. Continuing risk for hepatitis B virus transmission among 
Southeast Asian infants in Louisiana. Pediatrics 1995;96:1113–6; Franks AL, Berg CJ, Kane MA, et al. Hepatitis B infection among children born in the 
United States to southeast Asian refugees. N Engl J Med 1989;321:1305. 
transmitted disease [STD]/HIV testing and treatment facili- Public Health Management 
ties, drug-abuse treatment and prevention settings, health-care of HBsAg-Positive Persons 
settings targeting services to IDUs, health-care settings tar-
The finding of HBsAg in serum is indicative of chronic geting services to MSM, and correctional facilities) should 
HBV infection unless the person has signs or symptoms of receive the first dose of vaccine at the same medical visit after 
acute hepatitis. All HBsAg-positive laboratory results should blood is drawn for testing unless an established patient-
be reported to the state or local health department, in accor­provider relation can ensure that the patient will return for 
dance with state requirements for reporting of acute and serologic test results and that vaccination can be initiated at 
chronic HBV infection. Chronic HBV infection can be con-that time if the patient is susceptible. In venues where vacci­
firmed by verifying the presence of HBsAg in a serum sample nation is recommended and testing is not feasible, vaccina­
taken at least 6 months after the first test, or by the absence oftion still should be provided for all populations for whom it is 
IgM anti-HBc in the original specimen. Standard case defini­recommended. 
tions for the classification of reportable cases of HBV infec­
tion have been published previously (124). 
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Contact Management 
Sex partners and household and needle-sharing contacts of 
HBsAg-positive persons should be identified. Unvaccinated 
past and present sex partners and household and needle-
sharing contacts should be tested for HBsAg and for anti-
HBc and/or anti-HBs and should receive the first dose of 
hepatitis B vaccine as soon as the blood sample for serologic 
testing has been collected. Susceptible persons should com­
plete the vaccine series using an age-appropriate vaccine dose 
and schedule. Those who have not been vaccinated fully should 
complete the vaccine series. Contacts determined to be HBsAg­
positive should be referred for medical care. 
Health-care providers and public health authorities treat­
ing persons with chronic HBV infection should obtain the 
names of their sex contacts and household members and a 
history of drug use. Providers then can help to arrange for 
evaluation and vaccination of contacts, either directly or 
with assistance from state and local health departments. Con­
tact notification is well-established in public STD programs; 
these programs have the expertise to reach identified contacts 
of HBsAg-positive patients and might be able to provide guid­
ance on procedures and best practices, or in programs with 
sufficient capacity, offer assistance to other providers to reach 
identified contacts. With sufficient resources, identification 
of contacts should be accompanied by health counseling and 
include referral of patients and their contacts for other 
services when appropriate. 
The success of contact management for hepatitis B has var­
ied widely, depending on local resources. One study deter­
mined that approximately half of providers caring for patients 
with chronic HBV infection recommended contact vaccina­
tion, and <20% of contacts initiated vaccination (125). In 
the national perinatal hepatitis B prevention program, approxi­
mately 26% of all persons identified as contacts by HBsAg­
positive women were tested and evaluated for vaccination by 
public health departments (CDC, unpublished data, 2005). 
In several state and local programs with targeted efforts for 
adult hepatitis B prevention, up to 85% of identified contacts 
have been evaluated (CDC, unpublished data, 2005); how­
ever, many states and cities have no contact identification pro­
grams outside the perinatal hepatitis B prevention program. 
Given the potential for contact notification to disrupt net­
works of HBV transmission and reduce disease incidence, 
health-care providers should encourage patients with HBV 
infection to notify their sex partners, household members, and 
injection-drug–sharing contacts and urge them to seek medi­
cal evaluation, testing, and vaccination. 
Patient Education 
Medical providers should advise patients identified as HBsAg 
positive regarding measures they can take to prevent trans­
mission to others and protect their health or refer patients for 
counseling if needed. Patient education should be conducted 
in a culturally sensitive manner in the patient’s primary lan­
guage (both written and oral whenever possible). Ideally 
bilingual, bicultural, medically trained interpreters should be 
used when indicated. 
• To prevent or reduce the risk for transmission to others, 
HBsAg-positive persons should be advised to 
— notify their household, sex, and needle-sharing con­
tacts that they should be tested for markers of HBV 
infection, vaccinated against hepatitis B, and, if sus­
ceptible, complete the hepatitis B vaccine series; 
— use methods (e.g., condoms) to protect nonimmune 
sex partners from acquiring HBV infection from sexual 
activity until the sex partners can be vaccinated and 
their immunity documented (HBsAg-positive persons 
should be made aware that use of condoms and other 
prevention methods also might reduce their risks for 
HIV infection and other STDs); 
— cover cuts and skin lesions to prevent the spread of 
infectious secretions or blood; 
— clean blood spills with bleach solution (126); 
— refrain from donating blood, plasma, tissue, or semen; 
— refrain from sharing household articles (e.g., tooth­
brushes, razors, or personal injection equipment) that 
could become contaminated with blood; and 
— dispose of blood and body fluids and medical waste 
properly. 
• HBsAg-positive pregnant women should be advised of 
the need for their newborns to receive hepatitis B vaccine 
and hepatitis B immune globulin beginning at birth and 
to complete the hepatitis B vaccine series according to 
the recommended immunization schedule. 
• To protect the liver from further harm, HBsAg-positive 
persons should be advised to 
— seek health-care services from a provider experienced 
in the management of hepatitis B; 
— avoid or limit alcohol consumption because of the 
effects of alcohol on the liver, with referral to care pro­
vided for persons needing evaluation or treatment for 
alcohol abuse; and 
— obtain vaccination against hepatitis A (2 doses, 
6–18 months apart) if chronic liver disease is present. 
• When seeking medical or dental care, HBsAg-positive 
persons should be advised to inform those responsible for 
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their care of their HBsAg status so they can be evaluated 
and their care managed appropriately. 
Other counseling messages include the following: 
• HBV is not spread by breastfeeding, kissing, hugging, 
coughing, ingesting food or water, sharing eating utensils 
or drinking glasses, or casual touching (5). 
• Persons should not be excluded from school, play, child 
care, work, or other settings on the basis of their HBsAg 
status, unless they are prone to biting (127). 
• HBV-infected health-care workers should follow published 
guidelines (128) and applicable state laws and regulations 
regarding recommended practices to reduce the risk of 
HBV transmission in the workplace.* 
• Involvement with a support group might help patients 
cope with chronic HBV infection. 
Medical Management of Chronic 
Hepatitis B 
Because 15%–25% of persons with chronic HBV infection 
are at risk for premature death from cirrhosis and liver cancer, 
persons with chronic HBV infection should be evaluated soon 
after infection is identified by referral to or in consultation 
with a physician experienced in the management of chronic 
liver disease. When assessing chronic HBV infection, the phy­
sician must consider the level of HBV replication and the 
degree of liver injury. Injury is assessed using serial tests of 
serum aminotransferases (ALT and AST), and, when needed, 
liver biopsy (histologic activity and fibrosis scores). 
Initial evaluation of patients with chronic HBV infection 
should include a thorough history and physical examination, 
with special emphasis on risk factors for coinfection with HIV 
and HCV, alcohol use, and family history of HBV infection 
and liver cancer. Laboratory testing should assess for indica­
tors of liver disease (complete blood count and liver panel), 
markers of HBV replication (HBeAg, anti-HBe, HBV DNA), 
coinfection with HCV, HDV, and HIV, and antibody to hepa­
titis A virus (HAV) (if local HAV prevalence makes prevac­
cination testing cost effective) (109). Where testing is available, 
schistosomiasis (S. mansoni or S. japonicum) also should be 
assessed for persons from endemic areas (129) because schis­
tosomiasis might increase progression to cirrhosis or HCC in 
the presence of HBV infection (130,131). Persons with chronic 
HBV infection who are not known to be immune to HAV 
should receive 2 doses of hepatitis A vaccine 6–18 months 
apart. Baseline alfa fetoprotein assay (AFP) is used to assess 
* Disagreement exists internationally about best practices for avoiding 
transmission of HBV from health-care worker to patient (53). 
for evidence of HCC at initial diagnosis of HBV infection, 
and ultrasound in patients at risk of HCC (i.e., Asian men 
aged >40 years, Asian women aged >50 years, persons with cir­
rhosis, persons with a family history of HCC, Africans aged 
>20 years, and HBV-infected persons aged >40 years with per­
sistent or intermittent ALT elevation and/or high HBV DNA) 
(13,108). Liver biopsy (or, ideally, noninvasive markers) can be 
used to assess inflammation and fibrosis if initial laboratory 
assays suggest liver damage, as per published practice guide­
lines for liver biopsy in chronic HBV infection (13). 
Following an initial evaluation, all patients with chronic 
HBV infection, even those with normal aminotransferase lev­
els, should receive lifelong monitoring to assess progression of 
liver disease, development of HCC, need for treatment, and 
response to treatment. Frequency of monitoring depends on 
several factors, including family history, age, and the condi­
tion of the patient; monitoring schedules have been recom­
mended by several authorities (13,106,107,132). 
Therapy for hepatitis B is a rapidly changing area of clinical 
practice. Seven therapies have been approved by FDA for the 
treatment of chronic HBV infection: interferon alfa-2b, 
peginterferon alfa-2a, lamivudine, adefovir dipivoxil, entecavir, 
telbivudine, and tenofovir disoproxil fumarate (13,106,132, 
133). In addition, at least two other FDA-approved oral anti­
viral medications for HIV (clevudine and emtricitabine) are 
undergoing phase-3 trials for HBV treatment and might be 
approved soon for chronic hepatitis B. Treatment decisions 
are made on the basis of HBeAg status, HBV DNA viral load, 
ALT, stage of liver disease, age of patient, and other factors 
(13,32,134). 
Coinfection with HIV complicates the management of 
patients with chronic hepatitis B. When selecting antiretrovirals 
for HIV treatment, the provider must consider the patient’s 
HBsAg status to avoid liver-associated complications and 
development of antiviral resistance. Management of these 
patients has been described elsewhere (135). 
Serologic endpoints of antiviral therapy are loss of HBeAg, 
HBeAg seroconversion in persons initially HBeAg positive, 
suppression of HBV DNA to undetectable levels by sensitive 
PCR-based assays in patients who are HBeAg-negative and 
anti-HBe positive, and loss of HBsAg. Optimal duration of 
therapy has not been established. For HBeAg-positive patients, 
treatment should be continued for at least 6 months after loss 
of HBeAg and appearance of anti-HBe (13); for HBeAg­
negative/anti-HBe-positive patients, relapse rates are 80%– 
90% if treatment is stopped in 1–2 years (13). Viral resistance 
to lamivudine occurs in up to 70% of persons during the first 
5 years of treatment (32). Lower rates of resistance among 
treatment-naïve patients have been observed with adefovir 
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(30% in 5 years), entecavir (<1% at 4 years), and telbivudine 
(2.3%–5% in 1 year) (136) but more resistance might occur 
with longer usage or among patients who developed resistance 
previously to lamivudine. Although combination therapy has 
not demonstrated a higher rate of response than that using 
the most potent antiviral medication in the regimen, more 
studies are needed using combinations of different classes of 
different medications active against HBV to determine if com­
bination therapy will reduce the rate of the development of 
resistance. 
Development of Surveillance Registries 
of Persons with Chronic HBV Infection 
Information systems, or registries, of persons with chronic 
HBV infection can facilitate the notification, counseling, and 
medical management of persons with chronic HBV infection. 
These registries can be used to distinguish newly reported cases 
of infection from previously identified cases, facilitate and track 
case follow-up, enable communication with case contacts and 
medical providers, and provide local, state, and national esti­
mates of the proportion of persons with chronic HBV infec­
tion who have been identified. Public health agencies use 
registries for patient case management as part of disease con­
trol programs for HIV and tuberculosis; for tracking cancers; 
and for identifying disease trends, treatment successes, and 
outcomes. Chronic HBV registries can similarly be used as a 
tool for public health program and clinical management. 
Widespread registry use for chronic HBV infection will be 
facilitated by the development of better algorithms for 
deduplication (i.e., methods to ensure that each infected per­
son is represented only once), routine electronic reporting of 
laboratory results, and improved communication with labo­
ratories. 
A tiered approach to establishing a registry might allow pro­
grams to increase incrementally the number of data elements 
collected and the expected extent of follow-up as resources 
become available. The specific data elements to be included 
will depend upon the objectives of the registry and the feasi­
bility of collecting that information. At a minimum, suffi­
cient information should be collected to distinguish newly 
identified persons from those reported previously, including 
demographic characteristics and serologic test results. If an 
IgM anti-HBc result is not reported, information about the 
clinical characteristics of the patient (e.g., presence of symp­
toms consistent with acute viral hepatitis, date of symptom 
onset, and results of liver enzyme testing) and the reason for 
testing can help ensure that the registry includes only persons 
with chronic infection and excludes those with acute disease. 
Including data elements on ethnicity and/or country of birth 
can assist in targeting interventions, and information about 
contacts identified and managed and medical referrals made 
can be used to review program needs. 
Collaboration between the registry and the perinatal hepa­
titis B prevention program is important to ensure that the 
registry captures data on women and infants with chronic 
infection identified through the perinatal hepatitis B preven­
tion program. Conversely, the perinatal hepatitis B preven­
tion program can use registry data to identify outcomes for 
infants born to infected women who might have been lost to 
follow-up. Periodic cross-matches with local cancer registry 
and death certificate data can allow a program to estimate the 
contribution of chronic HBV infection to cancer and death 
rates. Guidelines that clarify how and when data with or with­
out personal identifiers are transmitted and used should be 
developed to facilitate the protection of confidential data. 
Implementation of Testing
 
Recommendations
 
Health departments provide clinical services in a variety of 
settings serving persons recommended for HBsAg testing, 
including many foreign-born persons, MSM, and IDUs. Ide­
ally, HBsAg testing should be available in venues such as home­
less shelters, jails, STD treatment clinics, and refugee clinics 
because of the increased representation of IDUs and former 
IDUs in homeless shelters (58% drug users [137]), substance 
abuse treatment programs (13%–50% IDUs [138,139]), and 
correctional facilities (25% IDUs [140]) and the over-
representation of IDUs and MSM in STD clinics (6% IDUs 
and 10% MSM [141]), prevalence of chronic HBV infection is 
likely to be higher in these settings. However, few states have 
resources to implement HBsAg testing programs in these set­
tings and rely instead on limited community programs for 
needed public health and medical management. 
In 2008, CDC supported adult viral hepatitis prevention 
coordinators (AVHPCs) in 49 states, the District of Colum­
bia, and five cities (Los Angeles, Chicago, New York City, 
Philadelphia, and Houston) who assist in integrating hepati­
tis A and hepatitis B vaccination, hepatitis B and hepatitis C 
testing, and prevention services among MSM, IDUs, and 
at-risk heterosexuals treated in STD clinics, HIV testing pro­
grams, substance abuse treatment centers, correctional facili­
ties, and other venues. AVHPCs can promote the 
implementation of hepatitis B screening for MSM and IDUs. 
Testing in refugee and immigrant health centers and other 
health-care venues is needed to reach U.S. residents born in 
regions with HBsAg prevalence of >2% (142); AVHPCs also 
can collaborate within these settings to ensure that persons 
from HBV-endemic regions are tested for HBsAg. 
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CDC’s perinatal hepatitis B prevention program provides 
case management for HBsAg-positive mothers and their 
infants, including educating mothers and providers about 
appropriate follow-up and medical management (143). This 
program currently identifies 12,000–13,000 HBsAg-positive 
pregnant women each year (CDC, unpublished data, 2007). 
Although perinatal prevention programs provide follow-up 
for infants born to HBV infected women, the majority of states 
and local perinatal prevention programs lack staff to offer care 
referrals for HBV infected pregnant women. 
Multiple health-care providers play a role in identifying 
persons with chronic HBV infection and should seek ways to 
implement testing for chronic HBV in clinical settings: pri­
mary care, obstetrician, and other physician offices, refugee 
clinics, TB clinics, substance abuse treatment programs, 
dialysis clinics, employee health clinics, university health clin­
ics, and other venues. Medical compliance with testing rec­
ommendations already is high for certain populations, 
particularly among those who typically receive care in hospi­
tals or other health-care settings in which HBsAg testing is 
routine. For example, 99% of pregnant women deliver their 
infants in hospitals and 89%–96% of them are tested for HBV 
infection (144; CDC, unpublished data, 2007), and suscep­
tible dialysis patients are tested monthly for HBsAg (119). 
However, compliance with testing recommendations is lower 
in other settings. One study indicated that testing was per­
formed for 30%–50% of persons born in regions with high 
HBsAg prevalence who were seen in public primary care clin­
ics (145). Even in settings in which persons are tested rou­
tinely for HBsAg, more efforts are needed to educate, evaluate, 
and refer clients for appropriate medical follow-up. CDC sup­
ports education and training grants that help educate provid­
ers to screen patients at risk for chronic hepatitis B. Prevention 
research is needed to guide the delivery of hepatitis B screen­
ing in diverse clinical and community settings. 
In addition, community outreach and education, conducted 
through developing partnerships between health departments 
and community organizations, is needed to encourage com­
munity members to seek HBsAg testing. These partnerships 
might be particularly important to overcome social and cul­
tural barriers to testing and care among members of racial 
and ethnic minority populations who are unfamiliar with the 
U.S. health-care system. Advisory groups of community rep­
resentatives, providers who treat patients for chronic hepatitis 
B, providers whose patient populations represent populations 
with high prevalence, and professional medical organizations 
can guide health departments in developing communications 
and prioritizing hepatitis B screening efforts. 
The lack of sufficient resources for management of infected 
persons can be a barrier to implementation of screening pro­
grams. All persons with HBV infection, including those who 
lack insurance and resources, will need ongoing medical man­
agement and possibly therapy. This demand for care will 
increase as screening increases, and additional providers will 
be needed with expertise in the rapidly evolving field of hepa­
titis B monitoring and treatment. 
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